Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin(®) with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology

BACKGROUND: A biosimilar needs to demonstrate its similarity to the originator reference product (RP) in terms of structural and functional properties as well as nonclinical and clinical outcomes. OBJECTIVES: The aim was to assess the analytical similarity between the trastuzumab biosimilar HLX02 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Liqi, Zhang, Erhui, Xu, Yanpeng, Gao, Wenyuan, Wang, Linlin, Xie, Michael Hongwei, Qin, Peilan, Lu, Lihong, Li, Sipeng, Shen, Pengcheng, Jiang, Weidong, Liu, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211197/
https://www.ncbi.nlm.nih.gov/pubmed/32072477
http://dx.doi.org/10.1007/s40259-020-00407-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211197/
https://www.ncbi.nlm.nih.gov/pubmed/32072477
http://dx.doi.org/10.1007/s40259-020-00407-0

Ejemplares similares